A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. This is an ASCO Meeting Abstract from the ...
Sure, this is a rat study, but the biomechanics are solid. Turns out, that critical shoulder angle is, critical after all.